Bone marrow and plasma FGF-23 in heart failure patients: novel insights into the heart-bone axis.

ABSTRACT:

Aims

Fibroblast growth factor 23 (FGF-23) is known to be elevated in patients with congestive heart failure (CHF). As FGF-23 is expressed in the bone but can also be expressed in the myocardium, the origin of serum FGF-23 in CHF remains unclear. It is also unclear if FGF-23 expressed in the bone is associated with outcome in CHF. The aim of the present study was to investigate FGF-23 levels measured in bone marrow plasma (FGF-23-BM) and in peripheral blood (FGF-23-P) in CHF patients to gain further insights into the heart-bone axis of FGF-23 expression. We also investigated possible associations between FGF-23-BM as well as FGF-23-P and outcome in CHF patients.

Methods and results

We determined FGF-23-P and FGF-23-BM levels in 203 CHF patients (85% male, mean age 61.3 years)

SUBMITTER: von Jeinsen B 

PROVIDER: S-EPMC6487718 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature